TNF Receptor

Tumor Necrosis Factor Receptor; TNFR

Tumor necrosis factor (TNF) is a major mediator of apoptosis as well as inflammation and immunity, and it has been implicated in the pathogenesis of a wide spectrum of human diseases, including sepsis, diabetes, cancer, osteoporosis, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel diseases.

TNF-α is a 17-kDa protein consisting of 157 amino acids that is a homotrimer in solution. In humans, the gene is mapped to chromosome 6. Its bioactivity is mainly regulated by soluble TNF-α–binding receptors. TNF-α is mainly produced by activated macrophages, T lymphocytes, and natural killer cells. Lower expression is known for a variety of other cells, including fibroblasts, smooth muscle cells, and tumor cells. In cells, TNF-α is synthesized as pro-TNF (26 kDa), which is membrane-bound and is released upon cleavage of its pro domain by TNF-converting enzyme (TACE).

Many of the TNF-induced cellular responses are mediated by either one of the two TNF receptors, TNF-R1 and TNF-R2, both of which belong to the TNF receptor super-family. In response to TNF treatment, the transcription factor NF-κB and MAP kinases, including ERK, p38 and JNK, are activated in most types of cells and, in some cases, apoptosis or necrosis could also be induced. However, induction of apoptosis or necrosis is mainly achieved through TNFR1, which is also known as a death receptor. Activation of the NF-κB and MAPKs plays an important role in the induction of many cytokines and immune-regulatory proteins and is pivotal for many inflammatory responses.



Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

(Rac)-Benpyrine

Cat. No.: HY-133807A

(Rac)-Benpyrine, a racemate of Benpyrine, is a potent and orally active **TNF-α** inhibitor. (Rac)-Benpyrine has the potential for **TNF-α** mediated inflammatory and autoimmune disease research.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(Rac)-BIO8898

Cat. No.: HY-122663

(Rac)-BIO8898 is a **CD40-CD154 co-stimulatory interaction** inhibitor. (Rac)-BIO8898 inhibits CD154 binding to CD40-Ig with an IC_{50} of 25 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

1,4-Dicaffeoylquinic acid

(1,4-DCQA)

Cat. No.: HY-N0358

1,4-Dicaffeoylquinic acid (1,4-DCQA) is a phenylpropanoid from Xanthii fructus, inhibits LPS-stimulated TNF-α production.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

5,7-Dimethoxyflavanone

Cat. No.: HY-N5054

5,7-Dimethoxyflavanone shows potent antimutagenic activity against MeIQ mutagenesis in Ames test using the S. typhimurium TA100 and TA98 strains. And 5,7-Dimethoxyflavanone significantly and dose-dependently inhibits the inflammatory mediato.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

7,3',4'-Tri-O-methylluteolin

(5-Hydroxy-3',4',7-trimethoxyflavone)

Cat. No.: HY-N7012

7,3',4'-Tri-O-methylluteolin (5-Hydroxy-3',4',7-trimethoxyflavone), a flavonoid compound, possesses potent anti-inflammatory effects in LPS-induced macrophage cell line mediated by inhibition of release of inflammatory mediators, NO, PGE2, and...



Purity: 99.28%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Adalimumab

(Anti-Human TNF-alpha, Human Antibody)

Cat. No.: HY-P9908

Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factorα (**TNF-α**).

Purity: 99.62%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

Anti-inflammatory agent 16

Cat. No.: HY-143410

Anti-inflammatory agent 16 (compound 14), a peptidomimetic, shows potent anti-inflammatory activity. Anti-inflammatory agent 16 reduces TNFα, NO, CD40 and CD86 expression level.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Apratastat

Cat. No.: HY-119307

Apratastat is an orally active, potent, and reversible dual inhibitor of **tumor necrosis factor-α converting enzyme (TACE)** and **matrix metalloproteinases (MMPs)** .



Purity: 99.28%
Clinical Data:
Size: 1 mg, 5 mg

Apremilast

(CC-10004)

Cat. No.: HY-12085

Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (**PDE-4**) with an IC_{50} of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC_{50} of 104 nM.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Apremilast-d5

(CC-10004-d5)

Cat. No.: HY-12085S

Apremilast D5 (CC-10004 D5) is a deuterium labeled Apremilast. Apremilast is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (**PDE-4**) with an IC_{50} of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC_{50} of 104 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

AQX-016A

Cat. No.: HY-115620

AQX-016A is an orally active and potent **SHIP1** agonist. AQX-016A can activate recombinant **SHIP1** enzyme in vitro and stimulate **SHIP1** activity. AQX-016A also can inhibit the **PI3K** pathway and TNFa production, can be useful for various inflammatory diseases research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Astilbin

Cat. No.: HY-N0509

Astilbin is a flavonoid compound and enhances **NRF2** activation. Astilbin also suppresses **TNF-α** expression and **NF-κB** activation.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

AX-024

Cat. No.: HY-107390

AX-024 is an orally available, first-in-class inhibitor of the **TCR-Nck** interaction that selectively inhibits TCR-triggered T cell activation with an IC_{50} ~1 nM. AX-024 modulates cell signaling by targeting **SH3** domains.



Purity: ≥98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AX-024 hydrochloride

Cat. No.: HY-107390A

AX-024 hydrochloride is an orally available, first-in-class inhibitor of the **TCR-Nck** interaction that selectively inhibits TCR-triggered T cell activation with an IC_{50} ~1 nM. AX-024 hydrochloride modulates cell signaling by targeting **SH3** domains.



Purity: 99.12%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Belantamab

(GSK2857914)

Cat. No.: HY-P9980

Belantamab (GSK2857914) is a humanised IgG1 anti-**BCMA (TNFRSF17)** monoclonal antibody. Belantamab can be used in the synthesis of antibody-drug conjugate (ADC), Belantamab mafodotin.

Belantamab

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Belimumab

(LymphoStat B)

Cat. No.: HY-P9952

Belimumab (LymphoStat B) is a human IgG1λ monoclonal antibody that inhibits **B-cell activating factor (BAFF)**. Belimumab can be used for systemic lupus erythematosus (SLE) research.

Belimumab

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Benpyrine

Cat. No.: HY-133807

Benpyrine is a highly specific and orally active **TNF-α** inhibitor with a K_D value of 82.1 μM. Benpyrine tightly binds to **TNF-α** and blocks its interaction with TNFR1, with an IC_{50} value of 0.109 μM.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Bioymifi

(DR5 Activator)

Cat. No.: HY-18377

Bioymifi (DR5 Activator), a potent TRAIL receptor **DR5** activator, binds to the extracellular domain (ECD) of DR5 with a K_d of 1.2 μM. Bioymifi can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

C 87

Cat. No.: HY-100735

C 87 is a novel small-molecule **TNFα** inhibitor; potently inhibits TNFα-induced cytotoxicity with an IC_{50} of 8.73 μM.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

C25-140

Cat. No.: HY-120934

C25-140, a first-in-class, orally active, and fairly selective **TRAF6-Ubc13** inhibitor, directly binds to TRAF6, and blocks the interaction of TRAF6 with Ubc13. C25-140 lowers TRAF6 activity, reduces **NF-κB** activation, and combats autoimmunity.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CDC801

Cat. No.: HY-U00179

CDC801 is a potent and orally active phosphodiesterase 4 (**PDE4**) and tumor necrosis factor-α (**TNF-α**) inhibitor with IC_{50} of 1.1 μM and 2.5 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

cis-Mulberroside A

(Mulberroside D)

Cat. No.: HY-N0619A

cis-Mulberroside A (Mulberroside D) is the cis-isomer of Mulberroside A. Mulberroside A is one of the main bioactive constituent in mulberry (Morus alba L.).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Cleomiscosin A

Cat. No.: HY-N3595

Cleomiscosin A is a coumarino-lignoid from branch of Macaranga adenantha. Cleomiscosin A is active against **TNF-alpha** secretion of the mouse peritoneal macrophages.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Cleomiscosin A-d3

Cat. No.: HY-N3595S

Cleomiscosin A-d3 is the deuterium labeled Cleomiscosin A. Cleomiscosin A is a coumarino-lignoid from branch of Macaranga adenantha. Cleomiscosin A is active against **TNF-alpha** secretion of the mouse peritoneal macrophages.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CPI-1189

Cat. No.: HY-100376

CPI-1189 is a TNF-α release inhibitor with antioxidant and neuroprotective properties. CPI-1189 is used for researches of HIV-associated neurotoxicity and thus is a candidate for neuroprotective therapy in humans suffered from HIV-associated CNS disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cynaropicrin

Cat. No.: HY-N2350

Cynaropicrin is a sesquiterpene lactone which can inhibit **tumor necrosis factor** (**TNF-α**) release with IC_{50}s of 8.24 and 3.18 μM for murine and human macrophage cells, respectively.



Purity: 97.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

D-Trimannuronic acid

Cat. No.: HY-N7699A

D-Trimannuronic acid, an alginate oligomer is extracted from seaweed. D-Trimannuronic acid can induce TNFα secretion by mouse macrophage cell lines. D-Trimannuronic acid can be used for the research of pain and vascular dementia.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Dacetuzumab

Cat. No.: HY-P99015

Dacetuzumab (SGN-40) is a humanized IgG1, **anti-CD40** monoclonal antibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]).

Dacetuzumab

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DCVC

(S-[(1E)-1,2-dichloroethenyl]--L-cysteine)

Cat. No.: HY-19717

DCVC (S-[(1E)-1,2-dichloroethenyl]--L-cysteine) is a bioactive metabolite of trichloroethylene (TCE). DCVC inhibits pathogen-stimulated pro-inflammatory cytokines IL-1β, IL-8, and **TNF-α** release from tissue cultures.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Desoxo-narchinol A

Cat. No.: HY-N8435

Desoxo-narchinol A is an orally active and potent anti-inflammatory agent. Desoxo-narchinol A can be isolated from the roots and rhizomes of Nardostachys jatamansi. Desoxo-narchinol A can be used for septic shock and inflammatory diseases research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dexanabinol

(HU-211) Cat. No.: HY-106387

Dexanabinol (HU-211) is an artificially synthesized cannabinoid derivative and lacks cannabimimetic effects.



Purity: 98.60%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg

DRI-C21045

Cat. No.: HY-120323

DRI-C21045 (compound 10) is a potent and selective inhibitor of the **CD40-CD40L** costimulatory protein-protein interaction (PPI) with an IC_{50} of 0.17 μM.



Purity: 98.26%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

Episappanol

Cat. No.: HY-N9315

Episappanol is a natural compound isolated from Caesalpinia sappan heartwood with anti-inflammatory activity. Episappanol significantly inhibits the **IL-6** and **TNF-α** secretion.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Etanercept

Cat. No.: HY-108847

Etanercept, a dimeric fusion protein that binds TNF, acts as a **TNF** inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive.

Etanercept

Purity: ≥96.0%
Clinical Data: Launched
Size: 1 mg, 5 mg

Fisetin

Cat. No.: HY-N0182

Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.



Purity: 98.87%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g

Forsythoside B

Cat. No.: HY-N0029

Forsythoside B is a phenylethanoid glycoside isolated from the leaves of Lamiophlomis rotata Kudo, a Chinese folk medicinal plant for treating inflammatory diseases and promoting blood circulation. Forsythoside B could inhibit **TNF-alpha**, **IL-6**, **IκB** and modulate **NF-κB**.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Gamma-glutamylcysteine TFA

(γ-Glutamylcysteine TFA) Cat. No.: HY-113402A

Gamma-glutamylcysteine (γ-Glutamylcysteine) TFA, an intermediate in glutathione (GSH) synthesis, is a dipeptide served as an essential cofactor for the antioxidant enzyme glutathione peroxidase (GPx).



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

Geraniin

Cat. No.: HY-N0472

Geraniin is a **TNF-α** releasing inhibitor with numerous activities including anticancer, anti-inflammatory, and anti-hyperglycemic activities, with an IC_{50} of 43 μM.

Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rc

(Panaxoside Rc) Cat. No.: HY-N0042

Ginsenoside Rc, one of major Ginsenosides from Panax ginseng, enhances GABA receptor$_A$ (**GABA$_A$**)-mediated ion channel currents (I_{GABA}). Ginsenoside Rc inhibits the expression of **TNF-α** and **IL-1β**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rh1

(Prosapogenin A2; Sanchinoside B2; Sanchinoside Rh1) Cat. No.: HY-N0604

Ginsenoside Rh1 (Prosapogenin A2) inhibits the expression of **PPAR-γ**, **TNF-α**, **IL-6**, and **IL-1β**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

GSK2245035

Cat. No.: HY-118250

GSK2245035 is a highly potent and selective intranasal **Toll-Like receptor 7 (TLR7)** agonist with preferential Type-1 interferon (IFN)-stimulating properties. GSK2245035 has **pEC_{50}**s of 9.3 and 6.5 for IFNα and TFNα.



Purity: 99.79%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Hispidol

((Z)-Hispidol)

Cat. No.: HY-102040

Hispidol ((Z)-Hispidol) is a potential therapeutic for inflammatory bowel disease; inhibits **TNF-α** induced adhesion of monocytes to colon epithelial cells with an **IC_{50}** of 0.50 μM.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Homoplantaginin

Cat. No.: HY-N1949

Homoplantaginin is a flavonoid from a traditional Chinese medicine Salvia plebeia with antiinflammatory and antioxidant properties. Homoplantaginin could inhibit **TNF-α** and **IL-6** mRNA expression, **IKKβ** and **NF-κB** phosphorylation.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Hypaconitine

Cat. No.: HY-N0267

Hypaconitine, an active and highly toxic constituent derived from Aconitum species, is widely used to treat rheumatism. IC50 value: Target: In vitro: The present study investigated the metabolism of hypaconitine in vitro using male human liver microsomes.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Infliximab

(Avakine; CT-P13)

Cat. No.: HY-P9970

Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to **TNF-α**. Infliximab prevents the interaction of **TNF-α** with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research.

Avakine

Purity: 90.30%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg

ISIS 104838

Cat. No.: HY-145726

ISIS 104838 is an antisense oligonucleotide drug that reduces the production of **tumor necrosis factor (TNF-alpha)**, a substance that contributes to joint pain and swelling in rheumatoid arthritis.

ISIS 104838

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Isoforskolin

(Coleonol B)

Cat. No.: HY-N6927

Isoforskolin is the principle active component of C. forskohlii native to China. Isoforskolin reduces the secretion of lipopolysaccharide (LPS)-induced cytokines, namely **TNF-α**, **IL-1β**, **IL-6** and **IL-8**, in human mononuclear leukocytes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kdo2-Lipid A ammonium

Cat. No.: HY-N8277

Kdo2-Lipid A ammonium is a chemically defined lipopolysaccharide (LPS) with endotoxin activity equal to LPS. Kdo2-Lipid A ammonium is highly selective for **TLR4**. Kdo2-Lipid A ammonium stimulates the release of both **TNF** and **PGE2**.

Purity: >98%
Clinical Data: Phase 4
Size: 5 mg, 10 mg, 25 mg

LEESGGGLVQPGGSMK

Cat. No.: HY-P3149

LEESGGGLVQPGGSMK, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.

LEESGGGLVQPGGSMK

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LEESGGGLVQPGGSMK acetate

Cat. No.: HY-P3149B

LEESGGGLVQPGGSMK acetate, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK acetate can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.

LEESGGGLVQPGGSMK (acetate)

Purity: 99.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

LEESGGGLVQPGGSMK TFA

Cat. No.: HY-P3149A

LEESGGGLVQPGGSMK TFA, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK TFA can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Licarin A

((+)-Licarin A)

Cat. No.: HY-N2252

Licarin A ((+)-Licarin A), a neolignan, significantly and dose-dependently reduces TNF-α production (IC_{50}=12.6 μM) in dinitrophenyl-human serum albumin (DNP-HSA)-stimulated RBL-2H3 cells. Anti-allergic effects. Licarin A reduces **TNF-α** and **PGD2** production, and **COX-2** expression.



Purity: 98.16%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY 303511

Cat. No.: HY-15643

LY303511 is a structural analogue of LY294002. LY303511 does not inhibit PI3K. LY303511 enhances **TRAIL** sensitivity of SHEP-1 neuroblastoma cells. LY303511 reversibly blocks **K**⁺ currents (IC_{50}=64.6±9.1 μM) in MIN6 insulinoma cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY 303511 hydrochloride

Cat. No.: HY-15643A

LY 303511 hydrochloride is a structural analogue of LY294002. LY303511 does not inhibit PI3K. LY303511 enhances **TRAIL** sensitivity of SHEP-1 neuroblastoma cells. LY303511 reversibly blocks **K**⁺ currents (IC_{50}=64.6±9.1 μM) in MIN6 insulinoma cells.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Madecassic acid

Cat. No.: HY-N0569

Madecassic acid is isolated from Centella asiatica (Umbelliferae). Madecassic acid has anti-inflammatory properties caused by **iNOS**, **COX-2**, **TNF-alpha**, **IL-1beta**, and **IL-6** inhibition via the downregulation of **NF-κB** activation in RAW 264.7 macrophage cells.



Purity: 98.34%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Mesaconitine

Cat. No.: HY-N0724

Mesaconitine is the main active component of genus aconitum plants.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Methylthiouracil

(MTU)

Cat. No.: HY-B0513

Methylthiouracil is an antithyroid agent. Methylthiouracil suppresses the production **TNF-α** and **IL-6**, and the activation of **NF-κB** and **ERK1/2**.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Mulberroside A

Cat. No.: HY-N0619

Mulberroside A is one of the main bioactive constituent in mulberry (Morus alba L.).



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Muscone

Cat. No.: HY-N0633

Muscone is the main active monomer of traditional Chinese medicine musk. Muscone inhibits **NF-κB** and **NLRP3** inflammasome activation. Muscone remarkably decreases the levels of inflammatory cytokines (**IL-1β**, **TNF-α** and **IL-6**), and ultimately improves cardiac function and survival rate.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

N-Formyl-Met-Leu-Phe

(fMLP; N-Formyl-MLF)

Cat. No.: HY-P0224

N-Formyl-Met-Leu-Phe (fMLP; N-Formyl-MLF) is a chemotactic peptide and a specific ligand of N-formyl peptide receptor (FPR). N-Formyl-Met-Leu-Ph is reported to inhibit **TNF-alpha** secretion.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Negletein

(5,6-Dihydroxy-7-methoxyflavone) Cat. No.: HY-N4285

Negletein is a neuroprotectant enhances the action of nerve growth factor and induces neurite outgrowth in PC12 cells. Negletein shows promising anti-inflammatory activity via inhibition of **TNF-α** and **IL-1β** with IC_{50} values of 16.4 and 10.8 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Neochlorogenic acid

(trans-5-O-Caffeoylquinic acid) Cat. No.: HY-N0722

Neochlorogenic acid is a natural polyphenolic compound found in dried fruits and other plants. Neochlorogenic acid inhibits the production of **TNF-α** and **IL-1β**. Neochlorogenic acid suppresses **iNOS and COX-2** protein expression.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

QNZ

(EVP4593) Cat. No.: HY-13812

QNZ (EVP4593) shows strong inhibitory effects on **NF-κB** transcriptional activation and **TNF-α** production with **IC_{50}**s of 11 and 7 nM, respectively. QNZ (EVP4593) is a neuroprotective inhibitor of **SOC** channel.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

R-7050

(TNF-α Antagonist III) Cat. No.: HY-110203

R-7050 (TNF-α Antagonist III) is a **tumor necrosis factor receptor** (**TNFR**) antagonist with greater selectivity toward **TNFα**.

Purity: 99.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Resatorvid

(TAK-242; CLI-095) Cat. No.: HY-11109

Resatorvid (TAK-242) is a selective **Toll-like receptor 4 (TLR4)** inhibitor. Resatorvid inhibits **NO, TNF-α** and **IL-6** production with **IC_{50}**s of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF.



Purity: 99.95%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Roquinimex

(Linomide; FCF89; ABR212616) Cat. No.: HY-13743

Roquinimex (Linomide; PNU212616; ABR212616) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity; inhibits angiogenesis and reduces the secretion of TNF alpha.



Purity: 98.93%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Semapimod tetrahydrochloride

(CNI-1493; CPSI-2364 tetrahydrochloride) Cat. No.: HY-15509A

Semapimod tetrahydrochloride (CNI-1493), an inhibitor of **proinflammatory cytokine** production, can inhibit **TNF-α**, **IL-1β**, and **IL-6**. Semapimod tetrahydrochloride inhibits TLR4 signaling (IC_{50}≈0.3 μM).



Purity: 98.43%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Shikonin

(C.I. 75535; Isoarnebin 4) Cat. No.: HY-N0822

Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent **TMEM16A chloride channel** inhibitor with an **IC_{50}** of 6.5 μM. Shikonin is a specific **pyruvate kinase M2 (PKM2)** inhibitor and can also inhibit **TNF-α** and **NF-κB** pathway.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

Sinensetin

(Pedalitin permethyl ether) Cat. No.: HY-N0297

Sinensetin is a methylated flavone found in certain citrus fruits. pocess potent antiangiogenesis and anti-inflammatory, sinensetin enhances adipogenesis and lipolysis.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Sinensetin-d3

Cat. No.: HY-N0297S

Sinensetin-d3 is the deuterium labeled Sinensetin. Sinensetin is a methylated flavone found in certain citrus fruits. pocess potent antiangiogenesis and anti-inflammatory, sinensetin enhances adipogenesis and lipolysis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

SPD304

Cat. No.: HY-111255

SPD304 is a selective **TNF-α** inhibitor, which promotes dissociation of TNF trimers and therefore blocks the interaction of TNF and its receptor. SPD304 has an IC_{50} of 22 μM for inhibiting in vitro TNF receptor 1 (TNFR1) binding to TNF-α.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg

SPD304 dihydrochloride

Cat. No.: HY-111255A

SPD304 dihydrochloride is a selective **TNF-α** inhibitor, which promotes dissociation of TNF trimers and therefore blocks the interaction of TNF and its receptor. SPD304 has an IC_{50} of 22 μM for inhibiting in vitro TNF receptor 1 (TNFR1) binding to TNF-α.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SR-318

Cat. No.: HY-135674

SR-318 is a potent and highly selective **p38 MAPK** inhibitor with IC_{50}s of 5 nM, 32 nM and 6.11 μM for p38α, p38β and p38α/β, respectively. SR-318 potently inhibits the **TNF-α** release in whole blood with an IC_{50} of 283 nM. SR-318 has anti-cancer and anti-inflammatory activity.



Purity: 98.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TIC10

(ONC-201)

Cat. No.: HY-15615A

TIC10 (ONC-201) is a potent, orally active, and stable tumor necrosis factor-related apoptosis-inducing ligand **(TRAIL)** inducer which acts by inhibiting Akt and ERK, consequently activating Foxo3a and significantly inducing cell surface TRAIL.



Purity: 99.80%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

TNF-α-IN-1

Cat. No.: HY-112275

TNF-α-IN-1 is a **TNF-α** inhibitor extracted from patent US20030096841A1, compound example I-7.



Purity: 98.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 250 mg

TNF-α-IN-2

Cat. No.: HY-134471

TNF-α-IN-2 is a potent and orally active inhibitor of **tumor necrosis factor alpha (TNFα)**, with an IC_{50} of 25 nM in the HTRF assay. TNF-α-IN-2 distorts the TNFα trimer upon binding, leading to aberrant signaling when the trimer binds to TNFR1.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TNF-α-IN-6

Cat. No.: HY-142618

TNF-α-IN-6 is an orally efficacious allosteric inhibitor of **TNFα** (K_D = 6.8 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRAF-STOP inhibitor 6877002

Cat. No.: HY-110247

TRAF-STOP inhibitor 6877002, is a selective inhibitor of **CD40-TRAF6** interaction, compound VII, shows inhibition of **NF-κB** activation in RAW cells, extracted from patent WO2014033122A1.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

UCB-9260

Cat. No.: HY-133122

UCB-9260, an orally active compound, inhibits **TNF signaling** by stabilising an asymmetric form of the trimer. UCB-9260 is selective for TNF over other superfamily members, and binds TNF with a similar K_d of 13nM.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Undecane

Cat. No.: HY-N8593

Undecane has anti-allergic and anti-inflammatory activities on sensitized rat basophilic leukemia (RBL-2H3) mast cells and HaCaT keratinocytes. In sensitized mast cells, Undecane inhibits degranulation and the secretion of histamine and **TNF-α**[1].

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

UTL-5g

(GBL-5g) **Cat. No.:** HY-117082

UTL-5g (GBL-5g), an anti-inflammatory **TNF-α** inhibitor, has chemoprotective and liver radioprotective effects. UTL-5g lowers hepatotoxicity, nephrotoxicity, and myelotoxicity induced by Cisplatin through TNF-α inhibition among other factors.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Varlilumab

(CDX-1127) **Cat. No.:** HY-P99057

Varlilumab (CDX-1127) is a first-in-class human IgG1 anti-**CD27** monoclonal antibody. Varlilumab has an anti-tumor activity.

Varlilumab

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VGX-1027

(GIT 27) **Cat. No.:** HY-15507

VGX-1027 is an orally active isoxazole compound that exhibits various immunomodulatory properties. VGX-1027 targets macrophages, reducing the production of the proinflammatory mediators TNF-α, IL-1β, IL-10.



Purity: 99.93%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg

Xanthine oxidase-IN-6

Cat. No.: HY-146560

Xanthine oxidase-IN-6 (Compound 6c) is a potent, orally active, mixed-type xanthine oxidase (**XOD**) inhibitor with an $\mathbf{IC_{50}}$ value of 1.37 μM. Xanthine oxidase-IN-6 shows strong **anti-hyperuricemia** and renal protective activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-Anhydroicaritin

Cat. No.: HY-N1940

β-Anhydroicaritin is isolated from Boswellia carterii Birdware, has important biological and pharmacological effects, such as antiosteoporosis, estrogen regulation and antitumor properties.



Purity: 98.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg